Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-25-100321
Filing Date
2025-10-17
Accepted
2025-10-17 12:02:41
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2528774d2_defa14a.htm DEFA14A 44700
2 EXHIBIT 2.1 tm2528774d2_ex2-1.htm EX-2.1 187440
3 EXHIBIT 99.1 tm2528774d2_ex99-1.htm EX-99.1 27510
4 GRAPHIC tm2528774d1_ex99-1img01.jpg GRAPHIC 8302
5 GRAPHIC tm2528774d1_ex99-1img02.jpg GRAPHIC 7401
  Complete submission text file 0001104659-25-100321.txt   282743
Mailing Address YALELAAN 62 UTRECHT Netherlands
Business Address YALELAAN 62 UTRECHT Netherlands 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40241 | Film No.: 251399403
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)